New drug SPG302 tested for schizophrenia in small trial
Symptom relief
Ongoing
This phase 2 study tests whether SPG302, a small synthetic molecule, can safely reduce schizophrenia symptoms in adults. 32 participants will receive either the drug or a placebo. Researchers will measure symptom severity, brain activity, and eye tracking to see if the drug works…
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC